Pegram MD - Search Results

1

Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.

Valero V, Forbes J, Pegram MD, Pienkowski T, Eiermann W, von Minckwitz G, Roche H, Martin M, Crown J, Mackey JR, Fumoleau P, Rolski J, Mrsic-Krmpotic Z, Jagiello-Gruszfeld A, Riva A, Buyse M, Taupin H, Sauter G, Press MF, Slamon DJ. Valero V, et al. Among authors: pegram md. J Clin Oncol. 2011 Jan 10;29(2):149-56. doi: 10.1200/JCO.2010.28.6450. Epub 2010 Nov 29. J Clin Oncol. 2011. PMID: 21115860 Clinical Trial.

2

Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.

Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ. Pietras RJ, et al. Among authors: pegram md. Oncogene. 1994 Jul;9(7):1829-38. Oncogene. 1994. PMID: 7911565

3

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.

Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ. Pegram MD, et al. Oncogene. 1997 Jul 31;15(5):537-47. doi: 10.1038/sj.onc.1201222. Oncogene. 1997. PMID: 9247307

4

Cytotoxicity and specificity of directed toxins composed of diphtheria toxin and the EGF-like domain of heregulin beta1.

Landgraf R, Pegram M, Slamon DJ, Eisenberg D. Landgraf R, et al. Biochemistry. 1998 Mar 3;37(9):3220-8. doi: 10.1021/bi972326z. Biochemistry. 1998. PMID: 9485477

5

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ. Pegram MD, et al. J Clin Oncol. 1998 Aug;16(8):2659-71. doi: 10.1200/JCO.1998.16.8.2659. J Clin Oncol. 1998. PMID: 9704716 Clinical Trial.

6

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.

Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ. Pietras RJ, et al. Among authors: pegram md. Oncogene. 1998 Oct 29;17(17):2235-49. doi: 10.1038/sj.onc.1202132. Oncogene. 1998. PMID: 9811454

7

HER-2/neu as a predictive marker of response to breast cancer therapy.

Pegram MD, Pauletti G, Slamon DJ. Pegram MD, et al. Breast Cancer Res Treat. 1998;52(1-3):65-77. doi: 10.1023/a:1006111117877. Breast Cancer Res Treat. 1998. PMID: 10066073 Review.

8

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.

Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D. Pegram M, et al. Oncogene. 1999 Apr 1;18(13):2241-51. doi: 10.1038/sj.onc.1202526. Oncogene. 1999. PMID: 10327070

9

Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity.

Pegram MD, Slamon DJ. Pegram MD, et al. Semin Oncol. 1999 Aug;26(4 Suppl 12):89-95. Semin Oncol. 1999. PMID: 10482199 Clinical Trial.

10

Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells.

Aguilar Z, Akita RW, Finn RS, Ramos BL, Pegram MD, Kabbinavar FF, Pietras RJ, Pisacane P, Sliwkowski MX, Slamon DJ. Aguilar Z, et al. Among authors: pegram md. Oncogene. 1999 Oct 28;18(44):6050-62. doi: 10.1038/sj.onc.1202993. Oncogene. 1999. PMID: 10557094

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

162 results

Search Page

Filters